The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely ...

The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny ...

The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their ...

Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...

The US Food and Drug Administration found no increased risk of suicidal behavior or ideation linked to popular weight-loss ...

The most shocking change in food labeling requirements comes from the FDA's decision to completely ban Red Dye No. 3 from food products, marking a monumental shift in food safety regulations. This ...

FDA Safety Changes: Zithromax, Frova, Lexiscan The FDA has approved safety labeling revisions for azithromycin tablets and oral suspension (Zithromax), frovatriptan succinate tablets (Frova), and ...